208 related articles for article (PubMed ID: 31620410)
21. A unicenter, prospective study of Guillain-Barré syndrome in Spain.
Sedano MJ; Orizaola P; Gallardo E; García A; Pelayo-Negro AL; Sánchez-Juan P; Infante J; Berciano J
Acta Neurol Scand; 2019 Jun; 139(6):546-554. PubMed ID: 30929269
[TBL] [Abstract][Full Text] [Related]
22. Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barré syndrome. Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group.
Lancet; 1997 Jan; 349(9047):225-30. PubMed ID: 9014908
[TBL] [Abstract][Full Text] [Related]
23. Treatment Efficacy of Plasmapheresis Versus Intravenous Immunoglobulin in Guillain-Barré Syndrome Management: A Systematic Review.
Savithri Nandeesha S; Kasagga A; Hawrami C; Ricci E; Hailu KT; Salib K; Butt S
Cureus; 2024 Mar; 16(3):e57066. PubMed ID: 38681292
[TBL] [Abstract][Full Text] [Related]
24. [Clinical consequences of neuromuscular impairments in critically ill patients].
Mesejo A; Pérez-Sancho E; Moreno E
Nutr Hosp; 2006 May; 21 Suppl 3():104-13. PubMed ID: 16768037
[TBL] [Abstract][Full Text] [Related]
25. The devil is in the detail: Acute Guillain-Barré syndrome camouflaged as neurosarcoidosis in a critically ill patient admitted to an Intensive Care Unit.
Sarada PP; Sundararajan K
Indian J Crit Care Med; 2016 Apr; 20(4):238-41. PubMed ID: 27303139
[TBL] [Abstract][Full Text] [Related]
26. Outcome of Guillain-Barré Syndrome in Tertiary Care Centers in Thailand.
Kulkantrakorn K; Sukphulloprat P
J Clin Neuromuscul Dis; 2017 Dec; 19(2):51-56. PubMed ID: 29189549
[TBL] [Abstract][Full Text] [Related]
27. CMV-associated axonal sensory-motor Guillain-Barré syndrome in a child: Case report and review of the literature.
Spagnoli C; Iodice A; Salerno GG; Frattini D; Bertani G; Pisani F; Fusco C
Eur J Paediatr Neurol; 2016 Jan; 20(1):168-75. PubMed ID: 26621312
[TBL] [Abstract][Full Text] [Related]
28. Changes in the severity and subtype of Guillain-Barré syndrome admitted to a specialist Neuromedical ICU over a 25 year period.
Taylor CJ; Hirsch NP; Kullmann DM; Howard RS
J Neurol; 2017 Mar; 264(3):564-569. PubMed ID: 28091723
[TBL] [Abstract][Full Text] [Related]
29. How Different is AMAN from AIDP in Childhood GBS? A Prospective Study from North India.
Gupta PK; Singhi P; Singhi S; Kasinathan A; Sankhyan N
Indian J Pediatr; 2019 Apr; 86(4):329-334. PubMed ID: 30637680
[TBL] [Abstract][Full Text] [Related]
30. Treatment of Guillain-Barré syndrome with intravenous immunoglobulin.
Sater RA; Rostami A
Neurology; 1998 Dec; 51(6 Suppl 5):S9-15. PubMed ID: 9851724
[TBL] [Abstract][Full Text] [Related]
31. Neuromuscular respiratory failure in Guillain-Barre Syndrome: evaluation of clinical and electrodiagnostic predictors.
Sundar U; Abraham E; Gharat A; Yeolekar ME; Trivedi T; Dwivedi N
J Assoc Physicians India; 2005 Sep; 53():764-8. PubMed ID: 16334619
[TBL] [Abstract][Full Text] [Related]
32. Guillain-Barré syndrome: epidemiology, pathophysiology and management.
Kuwabara S
Drugs; 2004; 64(6):597-610. PubMed ID: 15018590
[TBL] [Abstract][Full Text] [Related]
33. Intravenous immunoglobulin and Guillain-Barré syndrome.
Harel M; Shoenfeld Y
Clin Rev Allergy Immunol; 2005 Dec; 29(3):281-7. PubMed ID: 16391403
[TBL] [Abstract][Full Text] [Related]
34. Second IVIg course in Guillain-Barré syndrome patients with poor prognosis (SID-GBS trial): Protocol for a double-blind randomized, placebo-controlled clinical trial.
Walgaard C; Jacobs BC; Lingsma HF; Steyerberg EW; Cornblath DR; van Doorn PA;
J Peripher Nerv Syst; 2018 Dec; 23(4):210-215. PubMed ID: 30151941
[TBL] [Abstract][Full Text] [Related]
35. Neurologic complications of critical illness: part II. Polyneuropathies and myopathies.
Sanap MN; Worthley LI
Crit Care Resusc; 2002 Jun; 4(2):133-40. PubMed ID: 16573417
[TBL] [Abstract][Full Text] [Related]
36. Clinico-electrophysiological profile and predictors of functional outcome in Guillain-Barre syndrome (GBS).
Verma R; Chaudhari TS; Raut TP; Garg RK
J Neurol Sci; 2013 Dec; 335(1-2):105-11. PubMed ID: 24064258
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and safety of intravenous immunoglobulin retreatment amongst Guillain-Barré syndrome patients who poorly responded to initial IVIG cycle: a systematic review.
Prado MB; Adiao KJB; Turalde CWR; Dasig DA
Acta Neurol Belg; 2024 Mar; ():. PubMed ID: 38553651
[TBL] [Abstract][Full Text] [Related]
38. Acute polyradiculoneuritis: Guillain-Barré syndrome.
Korinthenberg R
Handb Clin Neurol; 2013; 112():1157-62. PubMed ID: 23622324
[TBL] [Abstract][Full Text] [Related]
39. Intravenous immunoglobulin in very severe childhood Guillain-Barré syndrome.
Singhi SC; Jayshree M; Singhi P; Banerjee S; Prabhakar S
Ann Trop Paediatr; 1999 Jun; 19(2):167-74. PubMed ID: 10690257
[TBL] [Abstract][Full Text] [Related]
40. Plasma exchange (PE) versus intravenous immunoglobulin (IVIG) for the treatment of Guillain-Barré syndrome (GBS) in patients with severe symptoms: A systematic review and meta-analysis.
Zaki HA; Iftikhar H; Najam M; Masood M; Al-Marri NDR; Elgassim MAM; Fayed M; Shaban EE
eNeurologicalSci; 2023 Jun; 31():100468. PubMed ID: 37288440
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
